Two patients were treated for inoperable, liver-dominant metastases, one from cutaneous melanoma and one from breast cancer. The treating physicians reported that both patients were treated successfully without procedure-related complications.
Thomas J Vogl, director of the Institute for Diagnostic and Interventional Radiology at JW Goethe, said, “We believe this technology has significant potential to help control cancers in the liver. We are pleased to be the first cancer centre to begin offering this important treatment option to patients in Germany, and are eager to further explore its role in the treatment of multiple tumor types including breast cancer.”
“Delcath’s partnership with JW Goethe reinforces the potential of Chemosat,” said Eamonn P Hobbs, president and CEO, Delcath. “We recently treated our first patients in Milan and are eager to continue our expansion across Europe. Opening another Chemosat treatment centre and treating patients in the continent’s largest market is another step forward in the commercialisation of this technology.”